IndustryCompany release

BrainsWay Q3 revenue climbs 34% to $18.1M on Deep TMS demand

Brainsway Ltd. (BWAY) · Tue 10 Nov 2026

The Nasdaq- and TASE-listed neurostimulation maker reports third-quarter operating and net profit, 130 system shipments, an $85M backlog and $63.4M in cash.

BrainsWay, which makes Deep TMS (transcranial magnetic stimulation) systems for psychiatric conditions, has published third-quarter 2026 results in a November investor presentation. Revenue rose 34% to $18.1M.

The company reported operating income of $2.6M and net income of $2.2M for the quarter. It shipped 130 systems in the period, and says its Deep TMS installed base is approaching 2,080 systems.

BrainsWay's balance sheet at quarter-end showed $63.4M in cash, and the company cites a backlog of $85M. The material was not accompanied by further detail on regional split, product mix or guidance in the information available to VigiEye.

The company also points to widening reimbursement for its therapy, citing expanding Medicare and commercial coverage that now spans more than 300M covered lives.

What it means for your team

  • Market-access teams in neuromodulation can note that BrainsWay reports broadening Medicare and commercial payer coverage, now above 300M covered lives.
  • Quality and post-market teams should expect a growing installed base, nearing 2,080 systems, to increase device surveillance and servicing workloads for the manufacturer.
  • The figures come from a company investor deck; they are self-reported and not independently verified.

Company's press release (SEC filing): Brainsway Ltd. ↗

Article written by VigiEye from the official source (Brainsway Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →